Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Dr. Roger Dansey Dr. Roger Dansey joins Ottimo Pharma Limited Board of Directors Dansey, a former senior executive at Pfizer ...

The addition of Seagen strengthened its position in oncology. Seagen generated sales of $3.4 billion in 2024, up 38% on a pro-forma basis.

Here is why it could be a smart buy now. Not every stock needs to be a millionaire-maker. Sometimes, slow and steady can win ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

In 2024, both Kate Middleton, Princess of Wales, and King Charles III told the world they had cancer.After each announcement, ...

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.